At a Glance
- Company: Vetter Pharma
- Location: Saarlouis, Saarland, Germany
- Deal value: €480m first phase
- Focus area: Sterile fill‑finish for high‑volume biologics injectables
- Next steps: Construction starts Q2 2026; EU state aid approved
What happened?
Vetter Pharma submitted building permit applications for a new commercial production plant in Saarlouis, Germany, as part of a €1.5bn global expansion. The first phase allocates €480m to a state-of-the-art sterile fill‑finish facility targeting high‑volume biologics, with construction starting Q2 2026 and operations from 2031.
Why does it matter?
Demand for injectable biologics outstrips capacity, driving outsourcing to CDMOs; Vetter’s investment addresses chronic fill‑finish bottlenecks for vials, syringes and cartridges amid oncology and autoimmune therapy growth. The site strengthens Europe’s supply chain resilience and regional economy with up to 2,000 skilled jobs.
Who’s behind it?
Vetter, a Ravensburg-based independent CDMO with 75+ years in aseptic processing, serves global pharma/biotech via sites in Germany, Austria and the US. The family-owned firm received €47m EU state aid approval.
How was it achieved?
The 95-acre former automotive site offers strategic logistics near Vetter’s HQ; multi-phase build prioritises commercial-scale sterile manufacturing with sustainability features like biomethane and photovoltaics.
What’s next?
Groundbreaking Q2 2026; parallel US clinical expansion; full site ramps to support client timelines through 2030s capacity crunch.
What are people saying?
Senator Udo J. Vetter: “Sustainable growth… balance between stability and expansion.” Managing Director Henryk Badack: “Reduce carbon footprint… climate protection and regional value creation.”